HIV and HCC in Africa: The H2A Consortium

非洲的艾滋病毒和肝癌：H2A 联盟

• 批准号: 10471411
• 负责人: Gregory D Kirk
• 金额: $ 99.06万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-09 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10471411
• 关键词: Address; Adopted; Advocate; Africa; Africa South of the Sahara; African; Age; Aging; Award; Biological Markers; Cause of Death; Chronic; Clinical; Clinical Data; Clinical Research; Collaborations; Country; Data; Development; Epidemiology; Etiology; Foundations; Funding; Goals; HIV; HIV Infections; Hepatitis B; Hepatitis B Infection; Hepatitis B Therapy; Hepatitis B Virus; Hepatitis C virus; Hepatocarcinogenesis; Human; Immune response; Incidence; Individual; Infection; Infrastructure; Intercept; Interruption; Intervention; Investigation; Investments; Lead; Liver; Liver Fibrosis; Liver diseases; Malignant Neoplasms; Measurement; Medical; Mentors; Monitor; Oncogenes; Pathway interactions; Patients; Persons; Pilot Projects; Population; Population Research; Praziquantel; Prevention strategy; Primary carcinoma of the liver cells; Process; Prospective cohort; Research; Research Design; Research Infrastructure; Research Personnel; Research Project Grants; Resource-limited setting; Resources; Risk; Risk Factors; Schistosoma mansonii infection; Senegal; Serum Albumin; Translational Research; Uganda; United States National Institutes of Health; Universities; Viral hepatitis; antiretroviral therapy; base; biobank; biomarker discovery; career development; chronic infection; co-infection; cohort; curative treatments; data quality; design; effective therapy; high risk; improved; innovation; mortality; multidisciplinary; novel; novel marker; predictive marker; prevent; prospective; recruit; response; scale up; screening; success; translational study; treatment strategy

Hepatocellular carcinoma (HCC) is a very common and lethal cancer in Africa, and as patients with HIV live longer, the HCC burden may increase. In prior studies, our team identified chronic infection with hepatitis B and C viruses (HBV, HCV), HIV and Schistosomiasis mansoni as independent risk factors for HCC. Compared to the US, HCC in sub-Saharan Africa occurs at younger age and more advanced stage with survival of only months. Proposed is an East and West African partnership between colleagues at Makerere University in Uganda, Fann University in Senegal and Johns Hopkins University focused on HIV and hepatocellular carcinoma (HCC) in Africa: The H2A Consortium. Building on long-standing collaborative research, mentoring and clinical activities in both countries, our overarching goal is to reduce the heavy burden of HCC in sub- Saharan Africa. We advocate investigating cancer interception strategies using appropriate medical treatments to interrupt or reverse the impact of these HCC-causing infections. We will accomplish this objective by developing local capacity and performing important research. Consortium activities are designed to enhance both the clinical, population and translational research infrastructure and individual African investigator capacity to conduct high-level, collaborative investigation of HIV, chronic infections and HCC. First, we will form a large, prospective cohort of HBV and HBV/HIV co-infected persons to define who needs HBV treatment, determine clinical responses, and characterize breakthrough HCC, while investigating novel biomarkers. To understand our data demonstrating synergistic interaction between chronic HBV and Sm infections, we will examine HBV clinical and immunological responses in the periphery and the liver in response to Sm treatment. HIV is investigated as a key modifier of these relationships in both projects. Integrated within our scientific agenda, early-stage African investigators will be provided mentoring and career development support while conducting a collaborative pilot project leveraging Consortium resources. The impact of our integrated research and capacity development activities will be establishment of the H2A Consortium as partnered Centers of Excellence on HIV and HCC in East and West Africa.

肝细胞癌（HCC）是非洲非常普遍且致命的癌症，随着HIV患者的活力 更长的时间，HCC负担可能会增加。在先前的研究中，我们的团队确定了乙型肝炎的慢性感染 和C病毒（HBV，HCV），HIV和血吸虫病Mansoni作为HCC的独立危险因素。比较的 对于美国，撒哈拉以南非洲的HCC发生在年轻时，而更高级的阶段仅生存 月份。拟议的是Makerere University的同事之间的东非和西非伙伴关系 乌干达，塞内加尔的范恩大学和约翰·霍普金斯大学专注于艾滋病毒和肝细胞 非洲癌（HCC）：H2A财团。在长期合作研究的基础上进行指导 在两国的临床活动中，我们的总体目标是减轻hcc的沉重负担 撒哈拉非洲。我们主张使用适当的医疗治疗调查癌症截获策略 中断或扭转这些引起HCC引起的感染的影响。我们将通过 发展当地能力并进行重要研究。财团活动旨在增强 临床，人口和转化研究基础设施和非洲调查人员的能力 为了进行高级，对艾滋病毒，慢性感染和HCC的合作调查。首先，我们将形成一个大型 HBV和HBV/HIV共同感染者的预期队列定义需要HBV治疗的人，确定 在研究新型生物标志物的同时，临床反应和突破性HCC的特征。理解 我们的数据证明了慢性HBV和SM感染之间的协同相互作用，我们将检查HBV 响应SM治疗时，周围和肝脏中的临床和免疫反应。艾滋病毒是 在这两个项目中都是这些关系的关键修饰符。集成在我们的科学议程中 在进行指导和职业发展支持时，非洲早期的调查员在进行指导和职业发展支持 一个合作的试点项目利用财团资源。我们综合研究的影响以及 能力开发活动将建立H2A财团作为合作中心 东非和西非的艾滋病毒和HCC卓越。